Track Spruce Biosciences, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Spruce Biosciences, Inc. SPRB · Stock Open Spruce Biosciences, Inc. in new tab

0.6772 USD
EPS
-1.24
P/B
0.40
ROE
-66.10
Beta
2.50
Target Price
2.75 USD
Loading chart...
Key Metrics
Earnings dateMarch 8, 2027
EPS-1.24
Book Value1.87
Price to Book0.40
Debt/Equity6.02
% Insiders7.752%
Estimates
Forward P/E-0.78
Forward EPS-0.96
Target Mean Price2.75

DCF valuation

Model fair value for Spruce Biosciences, Inc. (SPRB)
Result
Sign in to run the valuation for SPRB.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 2.75 USD (low 2.00, high 4.00)
Low 2.00
Mean 2.75
High 4.00
Price 0.6772
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Spruce Biosciences, Inc. Logo Spruce Biosciences, Inc. Analysis (SPRB)

United States Health Care Official Website Stock

Is Spruce Biosciences, Inc. a good investment? Spruce Biosciences, Inc. (SPRB) is currently trading at 0.6772 USD. Market analysts have a consensus price target of 2.75 USD. This suggests a potential upside from current levels.

Earnings Schedule: Spruce Biosciences, Inc. is expected to release its next earnings report on March 8, 2027. The market consensus estimate for Forward EPS is -0.96.

Investor FAQ

Does Spruce Biosciences, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Spruce Biosciences, Inc.?

Spruce Biosciences, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 8, 2027. The company currently has a trailing EPS of -1.24.

Company Profile

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Exchange Ticker
NMS (United States) SPRB
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion